| Literature DB >> 24417505 |
Anthony Booker1, Andy Suter, Ana Krnjic, Brigitte Strassel, Mire Zloh, Mazlina Said, Michael Heinrich.
Abstract
OBJECTIVES: Preparations containing saw palmetto berries are used in the treatment of benign prostatic hyperplasia (BPH). There are many products on the market, and relatively little is known about their chemical variability and specifically the composition and quality of different saw palmetto products notwithstanding that in 2000, an international consultation paper from the major urological associations from the five continents on treatments for BPH demanded further research on this topic. Here, we compare two analytical approaches and characterise 57 different saw palmetto products.Entities:
Keywords: 1H nuclear magnetic resonance spectroscopy; fatty acids; gas chromatography; metabolomics; saw palmetto
Mesh:
Substances:
Year: 2014 PMID: 24417505 PMCID: PMC4284019 DOI: 10.1111/jphp.12198
Source DB: PubMed Journal: J Pharm Pharmacol ISSN: 0022-3573 Impact factor: 3.765
Figure 1Daily dose of fatty acids based on the lowest daily dosage given on the package for each product analysed. White bars indicate monopreparations containing only saw palmetto as active constituent, dark bars combination preparations that in addition contain other ingredients like vitamins or other herbal extracts. For each product, the country and the specimen number are given.
Characteristics of the monopreparations comparing the difference between the amount of saw palmetto extract as declared on the package and the measured concentration of total fatty acids assuming the extract would consist 100% of fatty acids
| Sample number | Country | Tablet (t) or hard gel capsule (hc) or soft gel capsule (sc) | Amount of saw palmetto extract per unit (mg) as declared on package | Total fatty acids (mg) per unit measured | Difference declaration versus measurement (%) |
|---|---|---|---|---|---|
| SP8 | ES | t | 80 | 368.3 | 460.4 |
| SP37 | CA | sc | 80 | 253.06 | 316.3 |
| SP34 | US | sc | 160 | 378.2 | 236.4 |
| SP53 | US | sc | 160 | 354.61 | 221.6 |
| SP54 | US | sc | 320 | 444.31 | 138.8 |
| SP36 | CH | sc | 160 | 151.56 | 94.7 |
| SP33 | FI | sc | 320 | 290.24 | 90.7 |
| SP49 | US | sc | 320 | 285.68 | 89.3 |
| SP35 | CH | sc | 320 | 281.34 | 87.9 |
| SP27 | CH | sc | 320 | 274.53 | 85.8 |
| SP31 | CH | sc | 320 | 274.45 | 85.8 |
| SP32 | KR | sc | 320 | 271.9 | 85.0 |
| SP30 | CH | sc | 320 | 271.82 | 84.9 |
| SP29 | KR | sc | 320 | 237.74 | 74.3 |
| SP12 | ES | hc | 160 | 55.68 | 34.8 |
| SP45 | CA | hc | 350 | 51.01 | 14.6 |
| SP14 | UK | hc | 300 | 34.5 | 11.5 |
| SP13 | CA | hc | 500 | 56.8 | 11.4 |
| SP11 | UK | hc | 450 | 44.57 | 9.9 |
Also contains saw palmetto powder.
Figure 2The percentage of each single fatty acid measured for each product. The bar ‘Ø registered’ shows the value of all registered products, ‘Ø mono’ the average values of all 19 monopreparations and ‘Ø combi’ the average values of all the 27 combination products. For each product, the country and the specimen number are given.
Figure 3Ellipse scores plot showing soft gel extracts in chloroform-d (SP25 – SP37).
Figure 4Bar chart showing loadings plot for soft gel extracts in chloroform-d (SP25 – SP37).
Figure 5Ellipse scores plot based on NMR spectroscopy data for saw palmetto crude powders and powder extracts in methanol-d4 (SP6–SP15) versus multicombination formulae in methanol-d4 (SP1, SP22, SP23, SP24).
Figure 6Ellipse scores plot based on NMR spectroscopy data for saw palmetto soft gel extracts (SP25–SP37) versus multicomponent formulae in chloroform-d (SP16–SP21).